I am looking forward to working together with the wider IQ-EQ Group Management Team to cement IQ-EQ's position as the leading global partner to private market investors where relationships are built ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

This week’s Bulls N’ Bears Runner of the Week is… Kalgoorlie Gold Mining. The company’s share price rocketed after a new ...

Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great effectiveness when compared to the generally used standard-of-care therapy ...

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

Mikko Koskimies, CEO of eQ Plc and Managing Director of eQ Asset Management Ltd, left these positions at the end of October 2024 due to a serious illness. Koskimies passed away in November. Mikko was ...

In this paper, we investigate a novel low-RF-chain technique, termed as phase-shifter-aided spatial multiplexing (PSSM), in the context of frequency-selective channels. Base on the single-carrier ...